Targets › CLK2
3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Apr 2027.
Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. (UniProt, P49760)
Open in Phaseline: the race on CLK2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas | Cirtuvivint (SM08502) CLK1-4 and DYRK1-4 kinase inhibitor | CLK1, CLK2, CLK3, CLK4, DYRK1 | Phase 2 | Soft Tissue Sarcoma (STS) | Apr 2027 |
| Washington University School of Medicine | Cirtuvivint CDC2-like kinase (CLK) and dual-specificity tyrosine-regulated kinase (DYRK) inhibitor | CLK1, CLK2, CLK3, CLK4 | Phase 1 | Small-cell Lung Cancer | Jul 2028 |
| University of Colorado, Denver | Cirtuvivint Pan CDC-like kinase (CLK) and dual specificity tyrosine kinase (DYRK) inhibitor with Wnt i | CLK1, CLK2, CLK3, CLK4 | Phase 1 | Endometrioid Ovarian Cancer | Dec 2029 |
Small-cell Lung Cancer (1) Endometrioid Ovarian Cancer (1) Soft Tissue Sarcoma (STS) (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.